Outcomes4Me announced the acquisitions of Geno.Me and Realyze Intelligence as the company expands its AI-powered cancer care and clinical trial matching capabilities. The company also named Scot Stevens as a Strategic Advisor.
The acquisitions are designed to strengthen Outcomes4Me’s direct-to-patient oncology platform by combining patient medical record access, AI-powered data abstraction, and clinical trial matching technologies. Outcomes4Me said the combined technologies will help patients gain faster access to evidence-based treatment options and clinical trials while also supporting oncology research and commercial partnerships.
Outcomes4Me noted that it was the first direct-to-patient platform to integrate with the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), a relationship dating back to 2019. The company’s platform is designed to help patients access science-backed oncology guidance without fees or gatekeepers.
Geno.Me enables patients to access and securely share health data through integrations with major electronic health record systems, including Epic, Cerner, and Meditech. The platform was founded to improve patient representation and diversity in clinical research.
Realyze Intelligence, initially developed at UPMC with input from several NCI-Accredited Cancer Centers, uses AI to convert medical records into structured oncology-specific clinical data models. The technology identifies relevant clinical trial cohorts in seconds and is integrated directly into clinical workflows.
Outcomes4Me said the addition of Stevens as Strategic Advisor will support the integration of Realyze Intelligence into its broader patient-facing ecosystem. Stevens previously worked closely with Realyze Intelligence during its development.
The company said the acquisitions will enhance its ability to support more than 400,000 cancer patients through AI-driven clinical guidance, genomics insights, symptom tracking, and clinical trial matching. Outcomes4Me also said the platform provides pharmaceutical and research partners with access to real-world evidence and patient experience insights.
KEY QUOTES:
“The intersection of clinical research and direct patient care has long been both a technological priority and a challenge, I am optimistic that AI-powered clinical trial matching can close the gap between patients and potentially life-changing research opportunities. We have long focused on getting the right patients into the right clinical trials faster, at scale.”
Scot Stevens, Chief Information Officer, UPMC Hillman Cancer Center
“Together, Geno.Me and Realyze Intelligence’s unique ability to enable immediate medical records access and abstraction that aligns with our structured clinical data models, along with rapid clinical trial matching, supercharges our ability to support patients living with cancer. It also deepens our ability to help our commercial partners with both clinical trial recruitment and better understanding the patient experience through access to real-world evidence. By merging these technologies with our own, and welcoming Scot Stevens as a Strategic Advisor, we are building upon a foundation we’ve spent years establishing, putting more than 400,000 cancer patients at the center of their own care, armed with the same evidence and guidance their oncologists rely on, and now the most sophisticated AI-powered clinical trial matching available anywhere.”
Maya R. Said, Founder And CEO, Outcomes4Me
“I started Geno.Me because I recognized the lack of diversity and representation in clinical research. I believe all patients deserve immediate access to their own data and should choose how that data is securely utilized. Now, Outcomes4Me’s rich community of hundreds of thousands of patients can benefit from Geno.Me’s powerful platform to support both their own health and treatment, while also contributing to important research in oncology.”
Britt Gottschalk, Founder, Geno.Me
“Realyze Intelligence was created to address one of the most significant gaps in clinical research: patients are often unaware of relevant clinical trial opportunities, while trial sponsors struggle to identify patient populations that meet increasingly complex inclusion and exclusion criteria. We have fundamentally reimagined clinical trial matching at scale by embedding it directly into clinical workflows in a way that accelerates research, reduces costs, and improves patient outcomes. The combination of Realyze’s AI-powered clinical trial matching capabilities with a trusted, consumer-focused platform like Outcomes4Me, already relied upon by patients navigating their diagnoses and exploring treatment options, has the potential to be truly transformative for the future of precision medicine and patient access to care.”
Gilan El Saadawi, MD, PhD, Co-founder, Realyze Intelligence
